Relief Therapeutics Hldg Ag Stock Price, News & Analysis

Relief Therapeutics (RLFTY) has announced the termination of merger discussions with Renexxion, Inc. The talks, which began with a non-binding letter of intent in November 2024, were discontinued as key conditions for the transaction were not met within the required timeframe.

Despite the merger's discontinuation, Relief maintains a strong position with CHF 15 million in cash reserves and access to a CHF 50 million undrawn equity facility from their largest shareholder GEM. The company remains focused on advancing its core development programs and strategic objectives independently.

Relief will provide a detailed business update in their 2024 Annual Report, scheduled for release on April 10, 2025.

Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, RLFTY) announced that the European Patent Office (EPO) will grant a patent for its RLF-TD011 treatment on February 26, 2025. The patent, titled 'Therapeutic Uses of Oxidizing Hypotonic Acid Solutions,' will protect the company's proprietary hypochlorous acid solutions for treating epidermolysis bullosa (EB) wounds in European markets until 2040.

The treatment has already received orphan drug designation from the FDA, and Relief plans to seek qualified infectious disease product (QIDP) designation. The company recently reported positive results from its investigator-initiated clinical trial for RLF-TD011 and is preparing a pre-IND meeting package for FDA submission. Patent applications are also under review in other major markets, including the United States and China.

Relief Therapeutics (SIX:RLF, OTCQB:RLFTY) has announced the sale of its GOLIKE intellectual property and commercialization rights outside the United States to Nutrisens for CHF 1.2 million upfront, plus potential contingent payments. This transaction marks the completion of Relief's strategic transition from direct marketing to a partnership-based model.

Under the agreement, Nutrisens will manage GOLIKE's marketing and sales in European markets and take over existing third-party distribution agreements in other regions. Relief maintains U.S. rights, where GOLIKE is exclusively licensed to Eton Pharmaceuticals, and will continue global supply and development of line extensions.

Following the transaction, Relief reported a cash balance of CHF 15.3 million as of January 22, 2025. The company will focus on advancing its R&D programs in rare dermatology and metabolic disorders, while exploring potential expansion into gastrointestinal therapeutics through ongoing discussions with Renexxion.

Relief Therapeutics provided an update on its potential reverse merger with Renexxion, a private U.S. clinical-stage biotech company focused on gastrointestinal disorders therapies. Following their earlier non-binding letter of intent, both companies have made significant progress in transaction structuring and integration planning. The parties expect to sign a definitive merger agreement in Q1 2025.

Dr. Raghuram Selvaraju, Relief's board chairman, emphasized their focus on leveraging complementary strengths to maximize shareholder value. However, the company noted that there's no assurance of reaching a definitive agreement or completing the proposed transaction as planned.

Relief Therapeutics (RLFTY) announced final results from a clinical trial evaluating PKU GOLIKE for treating phenylketonuria (PKU). The study demonstrated superior metabolic control during prolonged fasting periods compared to standard amino acid protein substitutes. Key findings showed PKU GOLIKE achieved:

- 17.8% reduction in blood phenylalanine (Phe) levels (P=0.0484)
- 33.8% increase in blood tyrosine (Tyr) levels (P=0.0008)

The randomized, crossover, controlled trial was conducted at Birmingham Children's Hospital, UK, on pediatric patients with classical PKU. The results will be presented at the 2025 ACMG Annual Clinical Genetics Meeting in Los Angeles.

Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY) announced plans to file Form 15F with the SEC on December 17, 2024, to terminate its U.S. securities registration and reporting obligations. The company will maintain its primary listing on the SIX Swiss Exchange, continue its Level 1 ADR program, and maintain its OTCQB quotation.

The filing will immediately suspend SEC reporting requirements, including Forms 20-F and 6-K, with full termination expected 90 days after submission. This decision follows the company's previous choice not to pursue a U.S.-regulated exchange listing after filing Form 20-F in 2021. The move aims to reduce compliance costs while maintaining strategic flexibility.

Relief Therapeutics announced positive final results from its proof-of-concept clinical trial of RLF-TD011 for treating epidermolysis bullosa (EB), a rare genetic condition causing fragile skin and chronic wounds. The trial met its primary endpoint, showing a 24% decrease in S. aureus relative abundance (p=0.01) after eight weeks of treatment, correlating with wound size reduction. 78% of treated wounds closed during the treatment period. The treatment increased beneficial bacteria and microbiome diversity, with effects persisting through a four-week post-treatment period. The company plans to consult with the FDA to finalize development and regulatory plans.

Relief Therapeutics has signed a non-binding letter of intent for a reverse merger with Renexxion, a private U.S. biotech company focused on gastrointestinal disorders therapies. The proposed transaction values Relief's equity at USD 100 million and Renexxion's at USD 260 million, resulting in a 72.2% ownership for Renexxion shareholders and 27.8% for Relief shareholders. The combined entity would maintain listings on SIX Swiss Exchange and OTCQB. The deal includes a one-year post-closing reset mechanism and requires completion of due diligence, definitive agreement execution by December 31, 2024, Renexxion's private financing completion, and regulatory and shareholder approvals.

Relief Therapeutics announced the publication of a Plain Language Summary in Future Rare Diseases about PKU GOLIKE®, their treatment for phenylketonuria (PKU). The summary, co-authored by PKU specialists and patient associations, presents clinical study results comparing PKU GOLIKE® with standard amino acid formulations. The study showed that while both provide equal amino acid levels, PKU GOLIKE® delivers a more natural absorption pattern, similar to whole food proteins. This sustained absorption benefits PKU patients who need stable amino acid intake for metabolic balance. The publication aims to make complex scientific information more accessible to patients and caregivers.